CJC / IPA Blend
Co-lyophilized blend of CJC-1295 (no DAC / Mod-GRF 1-29) and Ipamorelin for in vitro GH-axis research. Pairs a GHRH analog with a selective GHS-R ghrelin-receptor agonist to study complementary growth-hormone secretagogue pathways in preclinical models.
Independently Tested. Verifiably Pure.
Every batch of CJC / IPA Blend is sent to an accredited independent laboratory before it ships. Here is exactly what we screen for - and the certificate that proves it.
What We Test Every Batch For
How CJC / IPA Blend Works
Two complementary peptides targeting the GH/IGF-1 axis through distinct pituitary receptors in research models
CJC-1295 GHRH-Receptor Agonism
CJC-1295 (no DAC), also known as Mod-GRF(1-29), is a tetra-substituted analog of human GHRH(1-29). It binds pituitary GHRH receptors on somatotrophs, stimulating cAMP-mediated pulsatile growth hormone release while resisting DPP-IV cleavage compared to native GHRH.
- Selective GHRH-receptor activation on somatotrophs
- Stabilizing D-Ala, Gln, Ala, Leu substitutions vs native GRF(1-29)
- Short serum half-life (~30 min) preserving GH pulsatility
Ipamorelin GHS-R Selective Activation
Ipamorelin is a pentapeptide GHRP that selectively activates the ghrelin/GHS-R1a receptor. In preclinical studies (Raun et al. 1998), it stimulates GH release without the marked ACTH, cortisol, or prolactin elevations seen with earlier GHRPs such as GHRP-6 or hexarelin.
- Selective GHS-R1a (ghrelin receptor) agonism
- Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
- No significant ACTH/cortisol/prolactin response in preclinical models
Synergistic GH/IGF-1 Axis Stimulation
GHRH analogs and GHRPs act through distinct receptors but converge on the somatotroph, producing greater-than-additive GH release in preclinical co-administration studies (Bowers, Frohman). The blend models combined GHRH-R + GHS-R stimulation for in vitro GH-axis investigations.
- Complementary GHRH-R (CJC-1295) and GHS-R (Ipamorelin) pathways
- Synergistic GH release reported in preclinical co-administration
- Downstream IGF-1 elevation used as a GH-axis biomarker
What Research Has Shown
Reported effects from peer-reviewed preclinical studies of the individual components
Research Applications
Primary preclinical research areas for combined GHRH-analog and GHRP investigation
GH/IGF-1 Axis Research
In vitro and animal-model studies of dual GHRH-R and GHS-R stimulation and resulting GH/IGF-1 dynamics. Used to probe somatotroph signaling, receptor crosstalk, and the magnitude of GH release relative to single-agent administration.
Teichman et al. 2006 ↗Pituitary Secretagogue Research
Pituitary somatotroph response models combining a GHRH analog with a selective GHS-R agonist. Useful for characterizing receptor occupancy, desensitization kinetics, and downstream second-messenger profiles of growth-hormone secretagogues.
Raun et al. 1998 ↗Body Composition Preclinical Studies
Animal models examining GH-driven changes in lean mass, adiposity, and IGF-1 signaling. CJC-1295 and Ipamorelin co-administration is used to amplify GH exposure while maintaining a pulsatile release pattern in preclinical body-composition research.
Teichman et al. 2006 ↗GH-Pulsatility Research
Preclinical investigations into GH pulse amplitude, frequency, and integration of GHRH and ghrelin-receptor inputs. The blend allows researchers to study how combined receptor activation modifies endogenous somatotroph pulse architecture in vitro.
Sinha et al. 2005 ↗Compound Information
Technical specifications and analytical profile for both blend components
Frequently Asked Questions
Common questions about CJC / IPA Blend research parameters
Sources & References
Peer-reviewed publications and preclinical studies database